CD19 and neoplasm: For example, the iPSC-derived CD19 CAR-hnCD16 T cells could efficiently recognize and kill both CD19+ CD20+ and CD19- CD20+ tumor cells when combined with anti-CD20 monoclonal antibody (Rituxan) (113).